A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

It should be used with a reduced-calorie diet and increased physical activity. Eli Lilly and Company (NYSE ... annually living with type 1 and type 2 diabetes in low- to middle-income countries ...

Today, only two companies—Novo Nordisk and Eli Lilly—have anti-obesity products on the market, but more companies will enter the space. This has happened before in the diabetes market ...

It is to be used together with a reduced-calorie diet and ... and re Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

Weight loss injectables like Ozempic have gained popularity in Bengaluru, with patients sourcing them from abroad. The ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

To know how much Ozempic (or a similar medication) will cost you, it’s important to know if your medical insurance will cover ...

Researchers have conducted the first national survey on public awareness and perceptions of food, health, and Food is ...

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is in hot pursuit.